All In Biotech

Drug Trial Radar · NCT06906341

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Apr 11, 2025

Primary completion

Dec 2027

Study completion Aug 2028

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

Conditions

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Neoplasms
  • Endometrial Cancer

Interventions

  • Relacorilant 150 mg once daily (QD)Drug

    Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.

  • Nab-paclitaxel 80 mg/m^2Drug

    Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

  • Bevacizumab 10 mg/kgDrug

    Bevacizumab is administered as IV infusion on Days 1 and 15.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Date of first dose until PD or death, up to 18 months

Locations

53 sites in 8 countries. Site status is shown where the registry gives one.

  • 004

    Birmingham, Alabama · Recruiting

  • 150

    Palo Alto, California · Recruiting

  • 278

    San Francisco, California · Recruiting

  • 014

    San Francisco, California · Recruiting

  • 032

    Aurora, Colorado · Recruiting

  • 544

    Fort Myers, Florida · Recruiting

  • 335

    Miami Beach, Florida · Recruiting

  • 543

    West Palm Beach, Florida · Recruiting

  • 001

    Chicago, Illinois · Recruiting

  • 518

    Minneapolis, Minnesota · Recruiting

  • 334

    Kansas City, Missouri · Recruiting

  • 521

    St Louis, Missouri · Recruiting

  • 292

    Albuquerque, New Mexico · Recruiting

  • 304

    Centerville, Ohio · Recruiting

  • 517

    Eugene, Oregon · Recruiting

  • 127

    Pittsburgh, Pennsylvania · Recruiting

  • 522

    Fairfax, Virginia · Recruiting

  • 300

    Norfolk, Virginia · Recruiting

  • 121

    Milwaukee, Wisconsin · Recruiting

  • 109

    Brussels, Belgium · Recruiting

  • 326

    Charleroi, Belgium · Recruiting

  • 325

    Hasselt, Belgium · Recruiting

  • 108

    Leuven, Belgium · Recruiting

  • 328

    Aalst, Belgium, Belgium · Recruiting

  • 306

    Lille, France · Recruiting

  • 307

    Nancy, France · Recruiting

  • 310

    Nice, France · Recruiting

  • 324

    Pierre-Bénite, France · Recruiting

  • 323

    Plérin, France · Recruiting

  • 308

    Toulouse, France · Recruiting

  • 519

    Aachen, Germany · Recruiting

  • 255

    Berlin, Germany · Recruiting

  • 520

    Kempten, Germany · Recruiting

  • 321

    Catania, Italy · Recruiting

  • 122

    Milan, Italy · Recruiting

  • 516

    Milan, Italy · Recruiting

  • 295

    Pavia, Italy · Recruiting

  • 124

    Rome, Italy · Recruiting

  • 293

    Torino, Italy · Recruiting

  • 319

    Treviso, Italy · Recruiting

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.